Europe

Feb 17, 2016
Following the consultation on the future of England's Cancer Drug Fund, Leela Barham reviews what the stakeholders are thinking.
Jan 27, 2016
It's an obvious question for every pharmaceutical executive — and the question no-one dares to answer: what happens if the UK leaves the EU?
Jan 04, 2016
Gülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Nov 30, 2015
The Parliamentary Assembly of the Council of Europe is the latest to clamber aboard the well-filled bandwagon now rumbling and rattling across Europe in an increasingly noisy debate over drug prices. Reflector reports.
Nov 25, 2015
The much awaited consultation on a ‘new’ Cancer Drugs Fund (CDF) in England has finally emerged. Leela Barham reports.
Nov 10, 2015
The new interim report on the UK's Accelerated Access Review, which aims to speed up access to innovation in the NHS, is lacking in detail, writes Leela Barham.
Nov 08, 2015
Some of the radical thinking on healthcare spending from a new EC specialist group offers robust food for thought, writes Reflector.
Oct 08, 2015
Pharmaceutical Executive
Leela Barham talks with the EMA's top medical officer, Hans-Georg Eichler, about a potentially game-changing drug approval program.
Oct 06, 2015
No-one can say England's Accelerated Access Review, which aims to “ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations" isn't aiming high, writes Leela Barham.
native1_300x100
lorem ipsum